Literature DB >> 8995439

Stimulation of platelet activation and aggregation by a carboxyl-terminal peptide from thrombospondin binding to the integrin-associated protein receptor.

D J Dorahy1, R F Thorne, J V Fecondo, G F Burns.   

Abstract

Thrombospondin, a major secretory product of the alpha-granules of activated platelets, is a large trimeric glycoprotein that plays an important role in platelet aggregation. On resting platelets, thrombospondin binds to a single receptor in a cation-independent manner, but upon platelet activation it binds at least two further, distinct receptors that are both dependent upon divalent cations. Each of these receptors on the platelet surface binds to different regions of the thrombospondin molecule, and such binding may be responsible for the multifunctional role of thrombospondin in aggregation. We show here that a peptide from the carboxyl terminus of thrombospondin, RFYVVMWK, directly and specifically induces the activation and aggregation of washed human platelets from different donors at concentrations of 5-25 microM. At lower concentrations the peptide synergizes with suboptimal concentrations of ADP to induce aggregation. Peptide affinity chromatography and immunoprecipitation with a monoclonal antibody were used to identify the receptor for the carboxyl-terminal peptide as the integrin-associated protein. The integrin-associated protein remained bound to the RFYVVMWK-containing peptide column when washed with a scrambled peptide in the presence of 5 mM EDTA, indicating a divalent cation-independent association. It is suggested that integrin-associated protein is the primary receptor for thrombospondin on the surface of resting platelets and is implicated in potentiating the platelet aggregation response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8995439     DOI: 10.1074/jbc.272.2.1323

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Promotion of neurite and filopodium formation by CD47: roles of integrins, Rac, and Cdc42.

Authors:  Motoaki Miyashita; Hiroshi Ohnishi; Hideki Okazawa; Hiroyasu Tomonaga; Akiko Hayashi; Tetsuro-Takahiro Fujimoto; Nobuhiko Furuya; Takashi Matozaki
Journal:  Mol Biol Cell       Date:  2004-06-23       Impact factor: 4.138

Review 2.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest.

Authors:  E Sick; A Jeanne; C Schneider; S Dedieu; K Takeda; L Martiny
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

3.  Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Authors:  David D Roberts; Sukhbir Kaur; Jeffrey S Isenberg
Journal:  Antioxid Redox Signal       Date:  2017-09-08       Impact factor: 8.401

Review 4.  Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.

Authors:  Jan Philipp Bewersdorf; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Anticancer Ther       Date:  2019-03-19       Impact factor: 4.512

5.  CD47 gene knockout protects against transient focal cerebral ischemia in mice.

Authors:  Guang Jin; Kiyoshi Tsuji; Changhong Xing; Yong-Guang Yang; Xiaoying Wang; Eng H Lo
Journal:  Exp Neurol       Date:  2009-02-20       Impact factor: 5.330

6.  Modulation of lipopolysaccharide-induced monocyte activation by heparin-binding protein and fucoidan.

Authors:  M Heinzelmann; H C Polk; F N Miller
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

7.  Glucose regulation of thrombospondin and its role in the modulation of smooth muscle cell proliferation.

Authors:  Laura A Maile; Lee B Allen; Christopher F Hanzaker; Katherine A Gollahon; Paul Dunbar; David R Clemmons
Journal:  Exp Diabetes Res       Date:  2010-06-20

8.  Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling.

Authors:  Jeff S Isenberg; Martin J Romeo; Christine Yu; Christine K Yu; Khauh Nghiem; Jude Monsale; Margaret E Rick; David A Wink; William A Frazier; David D Roberts
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

Review 9.  Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling.

Authors:  Jeff S Isenberg; William A Frazier; Murali C Krishna; David A Wink; David D Roberts
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

10.  CD47 and TLR-2 cross-talk regulates neutrophil transmigration.

Authors:  Alex C Chin; Bénédicte Fournier; Eric J Peatman; Titus A Reaves; Winston Y Lee; Charles A Parkos
Journal:  J Immunol       Date:  2009-10-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.